P19 EXTERNAL VALIDATION OF THREE EXISTING EARLY MYELOMA RELAPSE SCORES (BY EBMT, CIBMTR, AND GIMEMA) IN A SINGLE CENTER SHOWS MAJOR DIFFERENCES

por Beksac, M, Cengiz Seval, G, Civriz Bozdag, S, Toprak, SK, Kurt Yuksel, M, Topcuoglu, P, Arslan, O, Ozcan, M, Demirer, T, Ilhan, O, Gurman, G
Publicado 2023

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey

por Salihoglu, A., Elverdi, T., Karadogan, I., Paydas, S., Ozdemir, E., Erdem, G., Karadurmus, N., Akyol, G., Kaynar, L., Yegin, ZA, Sucak, G., Ozkocaman, V., Topcuoglu, P., Ozcan, M., Birtas, E., Goker, H., Baslar, Z., Ferhanoglu, B.
Publicado 2014